The firm is expecting Phase III readouts this year for its FGFR2b drug bemarituzumab and is advancing a second KRAS inhibitor to the clinic.

The United Kingdom aims to boost its life sciences profile as Aviva Capital Partners and Socius unveiled plans for a £1 ...

US biotech bluebird bio has announced plans to split into two this year, with a separate oncology business spinning ... after the FDA laid out additional manufacturing standards for its lead ...

Tevogen (TVGN) reaffirms its top-line revenue forecast for its oncology pipeline, projecting $1B in revenue in its launch year and a cumulative five-year estimate of between $10B and $14B. The ...

Pharmaceutical company Cipla is open to expanding its manufacturing footprint in the US, a move that can relatively de-risk ...